17/11/2015

Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A Fr

VISIT ASCO.org

Alvaro Marin

Home MeetingLibrary Abstracts 2014GenitourinaryCancersSymposium

Search

Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or

TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A French survey
The sector study.
Subcategory:
Renal Cell Cancer
Category:
Genitourinary Cancer
Meeting:
2014 Genitourinary Cancers Symposium
Session Type and Session Title:
General Poster Session C: Renal Cancer
Abstract Number:
509
Citation:
J Clin Oncol 32, 2014 (suppl 4; abstr 509)
Author(s):
Stephane Oudard, Florence Joly, Lionnel Geoffrois, Brigitte Laguerre, Nadine Houede, Philippe Barthelemy, Marine GrossGoupil, Vano Yann-Alexandre, Olivier Lucidarme, Franois Bidault, Nadia Kelkouli, Bernard Escudier; HEGP, Oncologie
Mdicale, Paris, France; Centre Franois Baclesse, Caen, France; Centre Alexis VAUTRIN, Vandoeuvre-ls-Nancy, France;
Centre Eugne Marquis, Rennes, France; CHU Nmes, Nmes, France; Hpitaux Universitaires de Strasbourg, Strasbourg,
France; CHU Bordeaux, Bordeaux, France; European Hospital Georges Pompidou, Paris, France; Pitie Salpetriere Hospital,
Paris, France; Gustave Roussy, Villejuif, France; Novartis, Paris, France; Department of Medical Oncology, Institut Gustave
Roussy, Villejuif, France
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret
symbol (^).
Abstract Disclosures
Abstract:
Background: In the RECORD-1 study, only 22% of the mRCC patients (pts) received eve in pure 2nd line. Thus more data in
real world are needed. A retrospective French survey, on a large patient population, was designed to evaluate efficacy for the
sequence TKI-eve and/or TKI-eve-TKI in mRCC. Methods: Between 10/08 and 10/12, 164 mRCC pts from 26 french centers,
http://meetinglibrary.asco.org/content/123918-142

1/4

17/11/2015

Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A Fr

who progressed on initial TKI and received eve as 2nd line were recorded. In these pts, 3rd line TKI was recorded. Primary
endpoint was Duration of Treatment (DT) of each sequence. Secondary endpoints were best radiological response for eve
evaluated by 2 independent radiologists, tolerability, dose reduction, overall survival from the start of first TKI (OS). Patients
characteristics: Amongst 164 pts, 144 pts with follow-up > 4 months since initiation of eve were evaluated, 59/144 pts received
TKI-eve-TKI. Before eve initiation: median age was 65 yrs, most pts were male (70.3%), had clear cell histology (92.3%), had
received sunitinib as first TKI (94.4%). Main comorbidities were: hypertension (43.8%), diabetes (15.3%), and
hypercholesterolemia (19.4%). At the time of eve initiation, MSKCC classification was good (24.4%), intermediate (61.5%) or
poor (14.1%). Results: median DT of eve was 4 months and 21% pts were treated >9 months with 2.9% PR and 67.6% SD by
central review. Correlation between response to first TKI and eve was observed. Dose reduction of eve for toxicity was 23.2%.
The most common toxicities (all grades) were: stomatitis (25.3%), PNI (13%), fatigue (40.7%), hyperglycemia (9.3%),
hypercholesterolemia (17.3%) and hypertriglyceridemia (22.8%). Median duration of TKI-eve sequence was 18 months
(IC95%: 15-20), and OS was 36 months (IC95%: 27-56). For TKI-eve-TKI sequence (59 pts), sorafenib was mostly used
(76.3%) with dose reduction and clinical benefit rate of 26.7% and 42.2% respectively. Median DT and OS were 24 and 41
months (IC95%: 19-29; 25-57) respectively. Conclusions: In real world experience, for mRCC pts receiving TKI-eve
sequence, median DT of eve is 4 months with OS of 36 months which compares favorably with RECORD1 and RECORD 3
trials respectively.

Abstracts by Stephane Oudard:

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the
Temporary Authorization for Use program in France.
Meeting: 2015 Genitourinary Cancers Symposium | Abstract No: 264 | First Author: Nadine Houede
Category: Genitourinary Cancer - Prostate Cancer - Advanced Disease
Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-nave metastatic prostate
cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.
Meeting: 2015 Genitourinary Cancers Symposium | Abstract No: 140 | First Author: Gwenaelle Gravis
Category: Genitourinary Cancer - Prostate Cancer - Advanced Disease
Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant
prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or
enzalutamide (E).
Meeting: 2015 Genitourinary Cancers Symposium | Abstract No: 139 | First Author: Matthew Raymond Smith
Category: Genitourinary Cancer - Prostate Cancer - Advanced Disease
More

Share This Page

ASSOCIATED POSTER

http://meetinglibrary.asco.org/content/123918-142

2/4

17/11/2015

Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A Fr

Meeting: 2014 Genitourinary Cancers Symposium

Presenter: Stephane Oudard
View Poster

HOME
ASCO-SEP
MOC
COURSE CATALOG
CERTIFICATES
TRAINING PROGRAMS
MEETING LIBRARY
Abstracts
Virtual Meeting
Educational Book
Meeting Slides
BOOKSTORE
CAREER CENTER
Back to the Top
Contact Us Privacy Policy Terms & Conditions American Society Of Clinical Oncology Conquer Cancer
Foundation Cancer.Net Journal Of Clinical Oncology Journal Of Oncology Practice
All content 2015 American Society of Clinical Oncology. All rights reserved. Unauthorized reproduction is prohibited. For
permission to re-use, please contact permissions@asco.org.

This online resource is supported by:

http://meetinglibrary.asco.org/content/123918-142

3/4

17/11/2015

Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A Fr

http://meetinglibrary.asco.org/content/123918-142

4/4